|
Reproductive
and Developmental Effects of Moxifloxacin on Female
Mice and Embryos
Hanaa M.
Roshdy
Cell Biology Department, National Research Center
Dokki, Cairo, Egypt
Abstract
Moxifloxacin (Avelox®) is a fluoroquinolone antibiotic with a broad spectrum of
activity and bactericidal action. Moxifloxacin has in
vitro activity against a wide range of Gram-positive and Gram-negative
organisms. The safe use of moxifloxacin in human
pregnancy has not been established. In order to evaluate the genotoxic and embryo toxic effects of (Avelox)® during pregnancy, Avelox was administrated orally to female mice with doses
(8.7, 17 and 26 mg/kg/day) from 1
to 17 days of pregnancy. Caesarean sections were completed on gestation day
18 and complete fetal examinations and cytogenetic
analysis were conducted. Decreases in the fetal body weights and increases in
the external visceral and skeletal anomalies were found in all doses of (8.7,
17 and 26 mg) Avelox compared to the controls. Cytogenetic analysis in mothers and embryos revealed that
all the tests doses produced chromosomal aberrations and micronuclei (MN)
formations in a dose dependent manner compared to the controls. These results
indicate that Avelox has a maternal and embryotoxic effects on the female mice and their embryos
when administered with a recommended and above the recommended dose during
pregnancy.
|